三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
戈利昔替尼与西达本胺的PFS曲线对比
戈利昔替尼与西达本胺的PFS曲线对比
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:138KB
图片尺寸:1107*848
同报告图片
/
4
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
fCDkuq7ngrkxIHwg5Lqu54K5MiB8IOS6rueCuTMgfAp8LS0tLS0tLXwtLS0tLS0tfC0tLS0tLS18Cnwg6Z225ZCR5YyF5ousRUdGUiBFeG9uMjBpbnPnqoHlj5jlnKjlhoXnmoTlpJrnp41FR0ZS56qB5Y+Y5Lqa5Z6LIHwg5L+d55WZ5a+5RUdGUuaVj+aEn+eqgeWPmOWPilQ3OTBN56qB5Y+Y55qE5oqX6IK/55ik5rS75oCnIHwg5pS55ZaE6I2v5Luj5Yqo5Yqb5a2m77yM5Lq65L2T5Y2K6KGw5pyf6ZW/6L6+57qmNTDlsI/ml7bvvIzmr4/ml6XkuIDmrKHlj6PmnI3lrp7njrDmjIHnu63nqLPlrprmipHliLYgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76ISJ6YCa77yM5Zu95YWD6K+B5Yi456CU56m25omA
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
所属报告:
迪哲医药-公司深度报告:小分子创新能力突出商业化前景良好-250617(24页).pdf
打包全文图表
相关数据
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
CARTITUDE-4 TME: Patients With Shorter PFS (≤18M) and Patients With More pLOT had a More Suppressive TME
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: PFS and OS in Patients With Standard-Risk Cytogenetics (As-Treated)
fCDnu4TliKsgfCAzMOS4quaciOaXoOi/m+WxleeUn+WtmOeOh++8iFBGUywgJe+8iSB8IDMw5Liq5pyI5oC755Sf5a2Y546H77yIT1MsICXvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSB8IDgwLjUgfCA4Ny4zIHwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSArIGdhaW4vYW1wKDFxKSB8IDcxLjcgfCA4Ni4xIHwKCui1hOaWmeadpea6kO+8mlBBUlRJVFVERSAtIDQg56CU56m277yI5qCH5YeG6aOO6Zmp57uG6IOe6YGX5Lyg5a2m5oKj6ICFIEFzIC0gVHJlYXRlZCDliIbmnpDvvInmlbDmja4=
收藏
行业数据
2026-03-11
原图定位
查看详情
Figure 3: PFS (A) and OS (B)
fCDmjIfmoIcgICAgICAgfCAzNuS4quaciOeOhyB8IDk1JSDnva7kv6HljLrpl7QgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgUEZTICAgICAgICB8IDkzLjglICAgIHwgNjMuMuKAkzk5LjEgICAgfAp8IE9TICAgICAgICAgfCA5My44JSAgICB8IDYzLjLigJM5OS4xICAgIHwKCui1hOaWmeadpea6kO+8muWbvueJh+S4reKAnFJlc3VsdHPigJ3mnb/lnZflj4pGaWd1cmUgM++8iFBGUyAoQSkg5ZKMIE9TIChCKe+8ieWGheWuueOAgg==
收藏
行业数据
2026-03-11
原图定位
查看详情
T-DXd对HER2-lowBC的全人群PFS
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
收藏
行业数据
2025-11-24
原图定位
查看详情
Ivonescimab国内临床,PFS显著优于K药
fCDmjIfmoIcgICAgICAgICAgICAgICAgfCDkvp3msoPopb/ljZXmipcobj0xOTgpICAgICAgIHwg5biV5Y2a5Yip54+g5Y2V5oqXKG49MjAwKSAgICAgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBtUEZTLCBtb3MgKDk1JSBDSSkgIHwgMTEuMTQgKDcuMzMsIE5FKSAgICAgICAgfCA1LjgyICg1LjAzLCA4LjIxKSAgICAgICB8CnwgU3RyYXRpZmllZCBIUiAoOTUlIENJKSB8IDAuNTEgKDAuMzgsIDAuNjkpICAgICAgfCAtICAgICAgICAgICAgICAgICAgICAgICB8CnwgcCAtIHZhbHVlICAgICAgICAgICB8IDwwLjAwMDEgICAgICAgICAgICAgICAgIHwgLSAgICAgICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya6b2Q6bKB5Yy76Zmi6IK/55ik5YaF56eR44CB5Lit6YKu6K+B5Yi456CU56m25omA
收藏
行业数据
2025-10-24
原图定位
查看详情
图表50艾玛昔替尼II/III期AS临床数据(应答率)
fCDmjIfmoIcgICAgICAgfCDlr7nnhafnu4TlupTnrZTnjocoJSkgfCDor5Xpqoznu4TlupTnrZTnjocoJSkgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18CnwgQVNBUzIwICAgICB8IDI5LjAgICAgICAgICAgICAgfCA0OC43ICAgICAgICAgICAgIHwKfCBBU0FTNDAgICAgIHwgMTguMyAgICAgICAgICAgICB8IDMyLjEgICAgICAgICAgICAgfAp8IEFTQVM1LzYgICAgfCAxNS42ICAgICAgICAgICAgIHwgNDIuOCAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpaLkxpIGV0IGFsLiBBIG11bHRpY2VudGVyLCByYW5kb21pemVkLCBkb3VibGUgLSBibGluZCw=
收藏
行业数据
2025-09-28
原图定位
查看详情
图表51艾玛昔替尼II/III期AS数据(较基线变化)
fCDmjIfmoIcgICAgICAgICAgfCBQbGFjZWJvIHwgU0hSMDMwMiA0IG1nIHwKfC0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgQkFTREFJICAgICAgICB8IC0xLjQzICAgfCAtMi4yMSAgICAgICAgfAp8IEJBU0ZJICAgICAgICAgfCAtMC43OSAgIHwgLTEuMzMgICAgICAgIHwKfCBCQVNNSSAobGluZWFyKXwgLTAuMjkgICB8IC0wLjQwICAgICAgICB8CnwgQVNRb0wgICAgICAgICB8IC0yLjE4ICAgfCAtMy4xMyAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaWi5MaSBldCBhbC4gQSBtdWx0aWNlbnRlciwgcmFuZG9taXplZCwgZG91YmxlLWJsaW5kLA==
收藏
行业数据
2025-09-28
原图定位
查看详情
izabren展现EGFRmNSCLC二线治疗历史最长PFS(单位:月)
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
收藏
行业数据
2025-09-16
原图定位
查看详情
图34、罗昔替尼各适症国内与美国发进
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
收藏
行业数据
2025-08-19
原图定位
查看详情
Vepdegestrantvs氟维司群在HR+/HER2-BC(全人群)的PFS数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
fCDpobnnm64gfCBCR0ItMTY2NzMgfCDljLnlronluIPmm7/lsLwgfAp8LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCBuICAgIHwgNjYgICAgICAgfCAxMTkgICAgICB8Cnwg5Lit5L2NUEZTLCDmnIggKDk1JSBDSSkgfCAyMi44ICgxNS42KSB8IDE0LjAgKDExLjItMTYuNikgfAp8IOS4reS9jemaj+iuv+aXtumXtCwg5pyIIHwgMTUuNiAgICAgIHwgMTkuNCAgICAgIHw=
收藏
行业数据
2025-08-07
原图定位
查看详情
CELESTIAL-301临床:全球唯一旨在证明相比目前固定疗程标准疗法具有PFS
fCDliIblsYLlm6DntKAgfCBB57uEIHwgQue7hCB8CnwtLS0tLS0tLS0tLXwtLS0tLXwtLS0tLXwKfCDlubTpvoQoPDY15bKB5a+55q+U4omlNjXlsoEpIHwgICAgIHwgICAgIHwKfCBJR0hWKOeqgeWPmOWvueavlOacqueqgeWPmCkgfCAgICAgfCAgICAgfAp8IOaYr+WQpuS8tOaciTE3cOe8uuWksS9UUDUz56qB5Y+YIHwgICAgIHwgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOa8lOekuuadkOaWme+8jOWbvemHkeivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-08-07
原图定位
查看详情
吉卡昔替尼乳膏临床试验情况(截至2025.05.29)
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
收藏
行业数据
2025-08-01
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
根据国家医保局材料,戈利昔替尼的 PFS 存在“拖尾效应”,18 个月的PFS 率接近 40%,为患者创造治愈的可能;戈利昔替尼停药率仅有 7.3%,总体耐受性更好。
行业数据
原图定位
当前图表所属:
迪哲医药-公司深度报告:小分子创新能力突出商业化前景良好-250617(24页).pdf
公司高管履历
舒沃替尼分子式及结构设计亮点
中国EGFRex20insNSCLC新发患者数量
全球EGFRex20insNSCLC新发患者数量
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》